These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

480 related items for PubMed ID: 19861575

  • 1. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy.
    Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ.
    Ann Oncol; 2010 May; 21(5):1046-52. PubMed ID: 19861575
    [Abstract] [Full Text] [Related]

  • 2. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ, Hu LY, Geng QR, Chen J, Lu ZH, Rao HL, Liu Q, Jiang WQ, Huang HQ, Lin TY, Xia ZJ.
    Chin J Cancer; 2016 Sep 13; 35(1):87. PubMed ID: 27624700
    [Abstract] [Full Text] [Related]

  • 3. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
    Guirguis HR, Cheung MC, Mahrous M, Piliotis E, Berinstein N, Imrie KR, Zhang L, Buckstein R.
    Br J Haematol; 2012 Oct 13; 159(1):39-49. PubMed ID: 22849793
    [Abstract] [Full Text] [Related]

  • 4. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
    Kridel R, Telio D, Villa D, Sehn LH, Gerrie AS, Shenkier T, Klasa R, Slack GW, Tan K, Gascoyne RD, Connors JM, Savage KJ.
    Br J Haematol; 2017 Jan 13; 176(2):210-221. PubMed ID: 27739058
    [Abstract] [Full Text] [Related]

  • 5. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
    Tai WM, Chung J, Tang PL, Koo YX, Hou X, Tay KW, Quek R, Tao M, Lim ST.
    Ann Hematol; 2011 Jul 13; 90(7):809-18. PubMed ID: 21229246
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.
    Gleeson M, Counsell N, Cunningham D, Chadwick N, Lawrie A, Hawkes EA, McMillan A, Ardeshna KM, Jack A, Smith P, Mouncey P, Pocock C, Radford JA, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D.
    Ann Oncol; 2017 Oct 01; 28(10):2511-2516. PubMed ID: 28961838
    [Abstract] [Full Text] [Related]

  • 8. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
    Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, Glass B, Scott DW, Gascoyne RD, Connors JM, Ziepert M, Pfreundschuh M, Loeffler M, Savage KJ.
    J Clin Oncol; 2016 Sep 10; 34(26):3150-6. PubMed ID: 27382100
    [Abstract] [Full Text] [Related]

  • 9. Secondary central nervous system involvement in 599 patients with diffuse large B-cell lymphoma: are there any changes in the rituximab era?
    Deng L, Song Y, Zhu J, Zheng W, Wang X, Xie Y, Lin N, Tu M, Ping L, Ying Z, Liu W, Zhang C.
    Int J Hematol; 2013 Dec 10; 98(6):664-71. PubMed ID: 24234713
    [Abstract] [Full Text] [Related]

  • 10. Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients.
    Ahn HK, Kim SJ, Yun J, Yi JH, Kim JH, Won YW, Kim K, Ko YH, Kim WS.
    Int J Hematol; 2010 Apr 10; 91(3):456-63. PubMed ID: 20198460
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab.
    Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, Bordessoule D, Recher C, Blanc M, Molina T, Lederlin P, Coiffier B.
    Ann Oncol; 2004 Jan 10; 15(1):129-33. PubMed ID: 14679132
    [Abstract] [Full Text] [Related]

  • 13. Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.
    Eyre TA, Kirkwood AA, Wolf J, Hildyard C, Mercer C, Plaschkes H, Griffith J, Fields P, Gunawan A, Oliver R, Booth S, Martinez-Calle N, McMillan A, Bishton M, Fox CP, Collins GP, Hatton CSR.
    Br J Haematol; 2019 Oct 10; 187(2):185-194. PubMed ID: 31222719
    [Abstract] [Full Text] [Related]

  • 14. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
    Tomita N, Takasaki H, Ishiyama Y, Kishimoto K, Ishibashi D, Koyama S, Ishii Y, Takahashi H, Numata A, Watanabe R, Tachibana T, Ohshima R, Hagihara M, Hashimoto C, Takemura S, Taguchi J, Fujimaki K, Sakai R, Motomura S, Ishigatsubo Y.
    Leuk Lymphoma; 2015 Mar 10; 56(3):725-9. PubMed ID: 24913502
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma.
    Wöhrer S, Püspök A, Drach J, Hejna M, Chott A, Raderer M.
    Ann Oncol; 2004 Jul 10; 15(7):1086-90. PubMed ID: 15205203
    [Abstract] [Full Text] [Related]

  • 17. Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone.
    Chen YB, Hochberg EP, Feng Y, Neuberg D, Rawal B, Motyckova G, Fisher DC, McAfee SL, Spitzer TR, Lacasce AS.
    Leuk Lymphoma; 2010 May 10; 51(5):789-96. PubMed ID: 20367136
    [Abstract] [Full Text] [Related]

  • 18. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
    Zinzani PL, Stefoni V, Finolezzi E, Brusamolino E, Cabras MG, Chiappella A, Salvi F, Rossi A, Broccoli A, Martelli M.
    Clin Lymphoma Myeloma; 2009 Oct 10; 9(5):381-5. PubMed ID: 19858058
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
    Ferrara F, Ravasio R.
    Clin Drug Investig; 2008 Oct 10; 28(1):55-65. PubMed ID: 18081361
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.